Relmada Therapeutics, Inc. (RLMD)
3.95
+0.14
(+3.67%)
USD |
NASDAQ |
Jan 22, 13:43
Relmada Therapeutics EPS Diluted (Quarterly): -0.304 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Amicus Therapeutics, Inc. | 0.0558 |
| Invivyd, Inc. | -0.0615 |
| Arcellx, Inc. | -0.9858 |
| Puma Biotechnology, Inc. | 0.1736 |
| NovaBay Pharmaceuticals, Inc. | -0.22 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.09M |
| Total Expenses (Quarterly) | 10.09M |
| Enterprise Value | 265.51M |
| Earnings Yield | -45.49% |
| Normalized Earnings Yield | -45.45 |